[go: up one dir, main page]

DK2405890T3 - Vandige riluzol-suspensioner - Google Patents

Vandige riluzol-suspensioner

Info

Publication number
DK2405890T3
DK2405890T3 DK10706234.1T DK10706234T DK2405890T3 DK 2405890 T3 DK2405890 T3 DK 2405890T3 DK 10706234 T DK10706234 T DK 10706234T DK 2405890 T3 DK2405890 T3 DK 2405890T3
Authority
DK
Denmark
Prior art keywords
riluzol
suspensions
around
riluzol suspensions
around riluzol
Prior art date
Application number
DK10706234.1T
Other languages
English (en)
Inventor
Roberta Artico
Marco Adami
Daniele Barbareschi
Jaime Moscoso
Tiziano Oldoni
Paolo Mascagni
Original Assignee
Italfarmaco Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40810549&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2405890(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Italfarmaco Spa filed Critical Italfarmaco Spa
Application granted granted Critical
Publication of DK2405890T3 publication Critical patent/DK2405890T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK10706234.1T 2009-03-13 2010-03-02 Vandige riluzol-suspensioner DK2405890T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09425101A EP2228054A1 (en) 2009-03-13 2009-03-13 Riluzole aqueous suspensions
PCT/EP2010/052598 WO2010102923A2 (en) 2009-03-13 2010-03-02 Riluzole aqueous suspensions

Publications (1)

Publication Number Publication Date
DK2405890T3 true DK2405890T3 (da) 2013-02-04

Family

ID=40810549

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10706234.1T DK2405890T3 (da) 2009-03-13 2010-03-02 Vandige riluzol-suspensioner

Country Status (22)

Country Link
US (1) US8765150B2 (da)
EP (2) EP2228054A1 (da)
JP (1) JP5607083B2 (da)
KR (1) KR101680175B1 (da)
CN (1) CN102341091B (da)
BR (1) BRPI1006418A2 (da)
CA (1) CA2748856C (da)
CL (1) CL2011002217A1 (da)
CO (1) CO6410281A2 (da)
CY (1) CY1113825T1 (da)
DK (1) DK2405890T3 (da)
ES (1) ES2400349T3 (da)
HK (1) HK1161985A1 (da)
HR (1) HRP20130021T1 (da)
MX (1) MX2011008922A (da)
PE (1) PE20120649A1 (da)
PL (1) PL2405890T3 (da)
PT (1) PT2405890E (da)
RU (1) RU2498802C2 (da)
SI (1) SI2405890T1 (da)
SM (1) SMT201300022B (da)
WO (1) WO2010102923A2 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014DN00200A (da) 2011-07-13 2015-06-05 Cytokinetics Inc
US10357497B2 (en) * 2012-06-23 2019-07-23 Biohaven Pharmaceutical Holding Company Limited Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis
HUE035023T2 (en) * 2014-11-20 2018-03-28 S I I T S R L Servizio Int Imballaggi Termosaldanti Diosmectic based pharmaceutical preparation
EP3220890A1 (en) * 2014-11-21 2017-09-27 Biohaven Pharmaceutical Holding Company Ltd. Sublingual administration of riluzole
HUE046869T2 (hu) * 2014-11-21 2020-04-28 Biohaven Therapeutics Ltd Riluzol szublingvális formulációja
US11911369B2 (en) * 2015-03-03 2024-02-27 Biohaven Therapeutics Ltd. Prodrugs of riluzole and their method of use
ITUB20155193A1 (it) * 2015-11-03 2017-05-03 Italfarmaco Spa Sospensioni orali di Givinostat fisicamente e chimicamente stabili
CN105726477B (zh) * 2016-03-01 2018-10-12 山东司邦得制药有限公司 一种小儿多潘立酮混悬液及其制备方法
CN108721325B (zh) * 2017-04-13 2020-03-06 辽宁大熊制药有限公司 蒙脱石混悬液及其制备方法
US20200289476A1 (en) * 2017-11-28 2020-09-17 University Of Houston System Liquid formulations of riluzole for oral and intravenous use
CN111437256A (zh) * 2019-01-17 2020-07-24 北京万全德众医药生物技术有限公司 一种利鲁唑缓释口服混悬液
CN115025056A (zh) * 2022-06-27 2022-09-09 郑州大学第一附属医院 一种含有替加氟、吉莫斯特和奥替拉西钾的口腔崩解制剂

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP249A (en) 1990-04-24 1993-03-17 Biota Scient Management Pty Ltd Anti-viral compounds.
FR2688138B1 (fr) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
FR2777781B1 (fr) * 1998-04-24 2004-04-09 Rhone Poulenc Rorer Sa Associations riluzole et l-dopa pour le traitement de la maladie de parkinson
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
PT1187612E (pt) * 1999-06-04 2005-05-31 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Utilizacao do riluzole para o tratamento da esclerose multipla
ATE289478T1 (de) 1999-08-12 2005-03-15 Lilly Co Eli Ektoparasitizide wässrige suspensionsformulierungen von spinosynen
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6432992B1 (en) 2000-06-05 2002-08-13 Aventis Pharm Sa Use of riluzole or its salts for the prevention and treatment of adrenoleukodystrophy
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6861413B2 (en) * 2001-05-22 2005-03-01 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
US7906145B2 (en) 2002-04-09 2011-03-15 Flamel Technologies Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)
WO2004045515A2 (en) 2002-11-15 2004-06-03 Teva Pharmaceutical Industries, Ltd. Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis
SI1477166T1 (sl) 2003-04-28 2006-12-31 Biofrontera Bioscience Gmbh Uporaba riluzola, kombiniranega s primernimi pomoznimi in dodatnimi snovmi, za zdravljenje bolezni,za katere je znacilna hiperproliferacija keratinocitov, se zlasti nevrodermitisa in psoriaze
US20050266032A1 (en) 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
US9492541B2 (en) 2004-09-14 2016-11-15 Sovereign Pharmaceuticals, Llc Phenylepherine containing dosage form
EP1778286A4 (en) 2004-03-03 2009-04-08 Teva Pharma COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE
US7691368B2 (en) * 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
ITMI20061274A1 (it) 2006-06-30 2008-01-01 Consiglio Nazionale Ricerche Vettori nanoparticellari lipidici contenenti riluzolo e composizioni farmaceutiche che li contengono
US9132071B2 (en) * 2006-07-28 2015-09-15 Santen Sas Compositions containing quaternary ammonium compounds
UA41879U (ru) * 2009-02-03 2009-06-10 Сергей Викторович Фурс Инфракрасный обогревательный прибор

Also Published As

Publication number Publication date
RU2011141422A (ru) 2013-04-20
WO2010102923A3 (en) 2011-03-03
US8765150B2 (en) 2014-07-01
US20120039953A1 (en) 2012-02-16
CL2011002217A1 (es) 2012-03-09
BRPI1006418A2 (pt) 2016-11-29
MX2011008922A (es) 2011-12-06
HK1161985A1 (en) 2012-08-17
CN102341091B (zh) 2013-08-07
PT2405890E (pt) 2013-02-20
EP2405890B1 (en) 2012-11-28
EP2228054A1 (en) 2010-09-15
EP2405890A2 (en) 2012-01-18
CO6410281A2 (es) 2012-03-30
CA2748856A1 (en) 2010-09-16
JP2012520254A (ja) 2012-09-06
CA2748856C (en) 2017-01-03
KR20120003854A (ko) 2012-01-11
CN102341091A (zh) 2012-02-01
ES2400349T3 (es) 2013-04-09
JP5607083B2 (ja) 2014-10-15
HRP20130021T1 (hr) 2013-02-28
SI2405890T1 (sl) 2013-02-28
WO2010102923A2 (en) 2010-09-16
PE20120649A1 (es) 2012-06-07
SMT201300022B (it) 2013-03-08
KR101680175B1 (ko) 2016-11-28
CY1113825T1 (el) 2016-07-27
RU2498802C2 (ru) 2013-11-20
PL2405890T3 (pl) 2013-04-30

Similar Documents

Publication Publication Date Title
DK2411442T4 (da) Umættet polyesterresin
DE112010004215A5 (de) Hydrostataktor
EP2469625A4 (en) OMNIBUS BAR
DK2427877T3 (da) Ophængningsindretning
EP2445547A4 (en) CATHETERISM SYSTEM
EP2397521A4 (en) BENZOXAZINE RESIN COMPOSITION
EP2407456A4 (en) CARBAZOLE ESTER-OXIME PHOTOINITIATOR
EP2401340A4 (en) POLYMER MODIFIER AGENTS
DK2430035T3 (da) Uracylspipooxetannukleosider
EP2509489A4 (en) SPRINKLER FOR EARLY HEEL REMOVAL
BRPI1008827A2 (pt) deisobutenizador
BRPI1014968A2 (pt) subalargador
DK2405890T3 (da) Vandige riluzol-suspensioner
DE112010002728A5 (de) Turboinhalator
DE112010004249A5 (de) Spindelaktor
DE112009005323A5 (de) Hebelarmprüfmaschine
BR112012004964A2 (pt) girocóptero
DK2483126T3 (da) Skinnekøretøj
EP2409976A4 (en) GLYCINE TRANSPORTER INHIBITOR
EP2401281A4 (en) PYRIMIDO-PYRIMIDO-INDAZOLE DERIVATIVE
DE112010004865T8 (de) Lamellennassreibkupplung
EP2418109A4 (en) SUSPENSION DEVICE
EP2454221A4 (en) cineole
EP2380788A4 (en) SAFETY BELT RETRACTOR
BR112012000654A2 (pt) estruturas de suspensao